KH617
Phase 2Small molecule
KH617 is one of 63 small molecule programs targeting Clinical Trial. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
62
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
136 competitors in Clinical Trial
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Avelox
BayerPhase 3
Venclexta
AbbViePhase 3
Paraplatin
AAvyxa
Phase 3
Opzelura
DDizal Pharmaceuticals
Phase 3
Potassium Iodide
MMeda Pharmaceuticals
Phase 3
Ablysinol
CSL BehringPhase 3
Nascobal
GGrupo Espanol de Tumores Neuroendocrinos
Phase 3
FOLFOXIRI
SSun Yat-sen University
Phase 3
JOINTSTEM
RR-Bio
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KH617. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details